OptimizeRx Corp. (NASDAQ:OPRX) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of OptimizeRx Corp. (NASDAQ:OPRX) have received a consensus rating of “Moderate Buy” from the nine ratings firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $11.4286.

A number of equities analysts recently issued reports on OPRX shares. UBS Group set a $11.00 price target on OptimizeRx in a report on Friday, August 14th. B. Riley Financial reduced their price objective on OptimizeRx from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Lake Street Capital decreased their price objective on OptimizeRx from $20.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Citigroup reissued a “market outperform” rating on shares of OptimizeRx in a report on Friday, August 14th. Finally, Citizens Jmp upped their price target on OptimizeRx from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research note on Friday, August 14th.

Hedge Funds Weigh In On OptimizeRx

Large investors have recently bought and sold shares of the company. Renaissance Technologies LLC boosted its holdings in shares of OptimizeRx by 633.2% in the first quarter. Renaissance Technologies LLC now owns 216,856 shares of the company’s stock valued at $1,362,000 after acquiring an additional 187,278 shares in the last quarter. Segall Bryant & Hamill LLC purchased a new position in OptimizeRx during the first quarter worth about $1,185,000. AWM Investment Company Inc. purchased a new position in OptimizeRx during the second quarter worth about $1,375,000. Next Century Growth Investors LLC lifted its position in OptimizeRx by 139.8% in the fourth quarter. Next Century Growth Investors LLC now owns 505,407 shares of the company’s stock valued at $6,196,000 after purchasing an additional 294,688 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in OptimizeRx by 22.3% in the first quarter. Dimensional Fund Advisors LP now owns 563,570 shares of the company’s stock valued at $3,540,000 after purchasing an additional 102,661 shares during the period. Hedge funds and other institutional investors own 76.47% of the company’s stock.

OptimizeRx Stock Down 1.5%

Shares of NASDAQ:OPRX opened at $7.86 on Wednesday. OptimizeRx has a 1-year low of $4.54 and a 1-year high of $22.25. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.58 and a quick ratio of 5.58. The stock has a market cap of $148.05 million, a P/E ratio of 34.18 and a beta of 1.08. The firm has a fifty day moving average price of $6.80 and a 200 day moving average price of $6.47.

OptimizeRx (NASDAQ:OPRX) last posted its quarterly earnings data on Wednesday, August 12th. The company reported $0.16 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.05. OptimizeRx had a net margin of 4.66% and a return on equity of 9.44%. The company had revenue of $20.50 million for the quarter, compared to analyst estimates of $20.20 million. Sell-side analysts predict that OptimizeRx will post 0.51 EPS for the current year.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.